Navigation Links
RxElite Files Registration Statement with Securities and Exchange Commission
Date:10/12/2007

MERIDIAN, Idaho, Oct. 12 /PRNewswire-FirstCall/ -- RxElite Holdings, Inc., a wholly owned operating subsidiary of Southridge Technology Group, Inc. (OTC Bulletin Board: SOUT) and a developer, manufacturer, and marketer of specialty generic prescription drug products, announced the filing of their Registration Statement with the Security and Exchange Commission for sale of shares from their recent round of financing.

"We are pleased to report that we are meeting our stipulated obligations with our investors promptly," commented Jonathan Houssian, the President and Founder of RxElite. "This is evidence of our growth as a public company and of the results oriented culture we have nurtured over the last 7 years."

RxElite filed the registration statement within the agreed to period detailed in their private placement concluded on July 13, 2007. The statement registers 53,747,555 shares of common stock, of which 35,831,706 were issued to investors in the private placement and the remainder that may be issued in the future through the exercise of warrants held by the same investors. Total shares of common stock outstanding for the company are 83,755,554. According to the private placement agreement, the recently registered shares must be declared effective within 90 days.

About RxElite Holdings, Inc.

RxElite Holdings, Inc. develops, manufactures, and markets generic prescription drug products in specialty generic markets. These markets include products in the areas of anesthesia, sterile liquid dose drugs (including respiratory inhalation drugs, ophthalmics, and injectable drugs), and transdermal patch products.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 involving known and unknown risks, delays, and uncertainties that may cause the our actual results or performance to differ materially from those expressed or implied by these forward-looking statements. These risks, delays, and uncertainties include, but are not limited to: risks associated with the uncertainty of future financial results, our reliance on our sole supplier, the limited diversification of our product offerings, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission. The Company's Form SB-2, filed with the SEC on October 10, 2007 details the registration of shares through the private placement. The Company undertakes no obligation to update any forward-looking statements.

Contact:

Corporate Information

Ph: (208) 288-5550

Toll Free: (800) 414-1901

Fax: (208) 288-1191

Investor Relations

Charlie Forshee, 215-885-4981

investorrelations@rxelite.com

Segue Ventures LLC


'/>"/>
SOURCE RxElite Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Novartis files application with FDA for Zometa
2. AAI Pharma Files Lawsuit Against Dr. Reddys Laboratories
3. Unfavourable Lipid-Lipoprotein profiles in older adults has been linked to abdominal visceral fat
4. Understanding Gene Profiles Could Help Cure A Resistant Form Of Leukemia In Kids
5. Personality profiles of gamblers and substance abusers are similar
6. NGO Files Pre-Grant Opposition Against Anti-HIV Drug, Combivir
7. Venus Remedies Files 5th International Patent Application
8. Shoaib Akhtar files appeal against ban
9. AIIMS Official Files Complaint Against Venugopal
10. Glaxo Files Cancer Drug For Approval With FDA
11. Nigeria Files New Lawsuit Against Pfizer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 2016 , ... First Choice Emergency Room , the largest network of ... Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased to ... said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/25/2016)... ... , ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter ... bar too high can result in disappointment, perhaps even self-loathing. However, those who set ... , Research from PsychTests.com reveals that behind the tendency to set low ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
(Date:6/24/2016)... 2016 Research and Markets has announced ... Diagnostic Tests" report to their offering. ... The World Market for Companion Diagnostics covers ... Market analysis in the report includes the following: ... Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
Breaking Medicine Technology: